In the process of evaluating the efficacy of the compounds in selected preclinical studies, a critical limitation remained their inability to assess the effect of the studied compounds on the tangle load (i.e., mature tau pathology) which represents a likely prerequisite for successful therapy of AD and related tauopathies. This evidence concerns the gene MAPT and Alzheimer disease.